The new environment of the healthcare market continues to create new strategic and business opportunities as a result of the Covid-19 pandemic. Healthcare providers have been prompted to shift their priorities to maintain stability during the crisis, creating openings for disruptors offering innovative services such as telemedicine, virtual care and remote patient monitoring. What are the likely near-term and longer-term drivers behind healthcare M&A and strategic partnership transactions? What has the shift done to valuations, and what type of deal structures are we seeing? How do dealmakers continue to find innovative companies and get capital to those that need it most?

Moderator: Armie Lee, Reporter, The Deal

Panelist: Adam Feinstein, Managing Partner, Vesey Street Capital Partners

Panelist: Brian Heaphy, Vice President, Corporate Development, Bristol-Myers Squibb

Panelist: Geoff Lieberthal, Partner, Two Sigma Impact

Panelist: Lenard Marcus, General Partner, Edison Partners

Panelist: Todd Rosenberg, Partner, Crowell & Moring

The digital health sector has experienced massive growth with the adoption of remote monitoring, telehealth and telemedicine services causing enormous disruptive changes in the market. Will the industry finally see advances in highly scalable machine learning and artificial intelligence solutions? Many experts feel that a shift to cloud-based EHR platforms that enable providers to access patient data anywhere, and communication and collaboration tools have strong potential for growth. What’s next for the digital health sector, and how are disruptive technologies changing the landscape of deals?

Moderator: Jordan Hamburger, Partner, Sheppard Mullin

Panelist: Amandine Ayrem, Managing Director, Mid-Large Buyout, Eurazeo

Panelist: Vinay Bhupathy, Partner, Sheppard Mullin

Panelist: Yash Kandoi, Principal, VSS

Panelist: Ezra Mehlman, Managing Partner, Health Enterprise Partners

The COVID-19 pandemic has had a profound impact on the way we live and work and with it comes uncertainty, altered daily routines, financial pressures and social isolation. In addition to the medical worries related to the virus, there is a drastic increase in mental health issues including depression, substance abuse, anxiety and suicide. The healthcare market is seeing a continued increase in demand for mental health services. This panel will explore how behavioral health M&A has become one of the most sought-after sectors in healthcare services and will examine the opportunities available for investors and innovative companies in the space.

Moderator: Mike Kaplan, Advisory Partner, Granite Growth Health Partners

Panelist: Christian Chauvet, Principal, Lee Equity Partners

Panelist: Matthew Evans, Managing Director & Head of Healthcare Finance, Monroe Capital

Panelist: Michael Fisher, Partner, Varsity Healthcare Partners

Panelist: Erin Lansky, Vice President, Blue Sea Capital

Amazon, Google, Apple and Facebook have a track record of disrupting major industries. Amazon acquired PillPack and Health Navigator and last year launched Amazon Pharmacy. The Apple Watch doubles as a virtual healthcare assistant, and their platform called Apple ResearchKit provides a platform for medical research. Alphabet’s moves in the health space include the purchase of Senosis Health, and Google’s acquisition of wearable device company Fitbit. Technology is contributing to a more competitive healthcare marketplace, but what will it take for tech companies to effectively get past the barriers of traditional healthcare delivery. Why is the sector not as competitive as it should be? This panel will delve into the strides taken by the tech companies in the healthcare space and what they might mean for the deal landscape.

Moderator: Chris Nolter, Senior Reporter, The Deal

Panelist: Ge Bai, Associate Professor of Accounting, Johns Hopkins Carey Business School

Panelist: Larry Gilmore, Senior Director, VSP Global

Panelist: Jesse Searby, Managing Director – Business Development, Thomas H. Lee Partners

Panelist: Brandon Weber, Co-Founder and Chief Executive Officer, Nava

Private Equity has record amounts of capital that needs to be deployed, but valuations and pricing are being severely affected by current market volatility. Dealmakers continue to be more cautious and selective, but buyers are looking to take advantage of opportunistic acquisitions. What businesses are seeing increased attention from healthcare private equity investors? How will the recovery effect pricing, valuations and risk allocation? This panel of dealmakers will share their perspective on the current state of private equity healthcare investing.

Moderator: Gregory Schernecke, Partner, Dechert

Panelist: Brad Armstrong, Partner, Lovell Minnick

Panelist: Benjamin Daverman, Managing Director, GTCR

Panelist: Andrew Kaplan, Principal, Bain Capital, Private Equity

Panelist: Steve Rodgers, Partner, Morgan Stanley Capital Partners

Panelist: Alissa Walker, Senior Associate, LorientCapital

Special Purpose Acquisition Companies (SPACs), also known as blank-check companies, have been around for the last 20 years or so, but have seen a recent resurgence as the market deals with high levels of liquidity, depressed valuations and a strong appetite for growth companies. SPACs raise money in an IPO and place it in a trust while the sponsor looks for a target to acquire. Once the companies complete the merger, the target company becomes a listed stock. What are the challenges that surround these transactions, and how are SPACs different from typical M&A transactions? Are their trends in Healthcare SPAC M&A that dealmakers need to be aware of?

Moderator: Bill Meagher, Senior Reporter, The Deal

Panelist: Andrew Bab, Partner, Debevoise & Plimpton

Panelist: Alan Mattamana, Partner, Fairview Capital